Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,118 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Rheumatoid Arthritis, NOS Clear all
Completed Phase 3 Interventional Results available

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

NCT02057250
View directory record Official record
Conditions
RA
Interventions
Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS), Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 7, 2026, 5:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome

NCT00001852
View directory record Official record
Conditions
Lymphoma, Salivary Gland Disease, Sjogren's Syndrome, Xerostomia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
4 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 7, 2026, 5:01 AM EDT
Active, not recruiting Phase 3 Interventional

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214
View directory record Official record
Conditions
Sjogren Syndrome
Interventions
VAY736, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Fullerton, California • La Palma, California • Brandon, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

NCT01313208
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
etanercept, Placebo, DMARD Therapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

NCT00686868
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
placebo, ofatumumab
Other · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Anniston, Alabama • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

NCT00652925
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 18 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
31
States / cities
San Diego, California • Hartford, Connecticut • Delray Beach, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2008 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

NCT03604406
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions
Varicella Zoster Vaccine, Placebo Injection
Biological · Other
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
5
States / cities
Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)

NCT01250548
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
apremilast, Placebo
Biological · Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 2Phase 3 Interventional

A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

NCT01830985
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
VX-509
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Upland, California • Fort Lauderdale, Florida • Venice, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 7, 2026, 5:01 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

NCT04035668
View directory record Official record
Conditions
Sjögren Syndrome
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

NCT00346216
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
celecoxib, Ibuprofen, Naproxen
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
24,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
871
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 515 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 7, 2026, 5:01 AM EDT
Not listed No phase listed Observational

Feasibility of an Immersive Virtual Reality Based Biofeedback Intervention for Outpatients in Rheumatology

NCT03459274
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Spondyloarthropathy, Vasculitis
Interventions
VR-Biofeedback
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Not applicable Interventional

A Nutritional Intervention for Arthritis

NCT01544101
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Vegan Diet, dietary supplement omega3 fatty acids aand vitamins
Other · Dietary Supplement
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 7, 2026, 5:01 AM EDT
Terminated Phase 3 Interventional Results available

An Open Label Study for Participants With Rheumatoid Arthritis

NCT01215942
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
127
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid Arthritis

NCT00327275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
strength training
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Not applicable Interventional

Cognitive-Behavioral Therapy and Tai Chi Chih for Patients With Rheumatoid Arthritis

NCT00072657
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cognitive Behavioral Therapy, Tai Chi Chih, Health Education Seminar
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

Nasal Spray Study in Sjogren's Dry Eye Disease

NCT05700422
View directory record Official record
Conditions
Sjogren's Syndrome, Dry Eye
Interventions
Varenicline Nasal Spray
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 7, 2026, 5:01 AM EDT
Terminated Phase 4 Interventional Results available

NSAIDs vs. Coxibs in the Presence of Aspirin

NCT03699293
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Diseases
Interventions
celecoxib 200mg capsule, naproxen sodium 550mg tablet, Aspirin 81mg tablet
Drug
Lead sponsor
Platelet and Thrombosis Research, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

NCT00487825
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Canakinumab (investigational), Placebo, Methotrexate (MTX)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome

NCT02701985
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Placebo, RO5459072
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Beverly Hills, California • Denver, Colorado • Baton Rouge, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 2Phase 3 Interventional

Health Promotion of People With Disabilities

NCT00164489
View directory record Official record
Conditions
Rheumatoid and Osteoarthritis
Interventions
Weight control and physical activity promotion
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 95 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 7, 2026, 5:01 AM EDT
Completed No phase listed Observational

Salivary Biomarkers for Sjögren's Syndrome Detection

NCT01807689
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 7, 2026, 5:01 AM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 7, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

Rheumatoid Arthritis Memory B Cells and Abatacept

NCT03652961
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, DMARDs
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 7, 2026, 5:01 AM EDT